69 related articles for article (PubMed ID: 9832352)
1. Serum concentrations of fluvoxamine and clinical effects. A prospective open clinical trial.
Härtter S; Wetzel H; Hammes E; Torkzadeh M; Hiemke C
Pharmacopsychiatry; 1998 Sep; 31(5):199-200. PubMed ID: 9832352
[TBL] [Abstract][Full Text] [Related]
2. Concentration-response relationship for fluvoxamine using remission as an endpoint: a receiver operating characteristics curve analysis in major depression.
Suzuki Y; Fukui N; Sawamura K; Sugai T; Watanabe J; Ono S; Inoue Y; Ozdemir V; Someya T
J Clin Psychopharmacol; 2008 Jun; 28(3):325-8. PubMed ID: 18480690
[TBL] [Abstract][Full Text] [Related]
3. Antidepressant response and fluvoxamine plasma concentrations: a pilot study.
Schwarzenbach F; Netillard C; Demoly P; Bisschop D; Limat S; Bouquet S; Vandel S; Bel AM; Woronoff-Lemsi MC
Pharm World Sci; 2003 Feb; 25(1):27-9. PubMed ID: 12661474
[TBL] [Abstract][Full Text] [Related]
4. The influence of lithium on fluvoxamine therapeutic efficacy and pharmacokinetics in depressed patients on combined fluvoxamine-lithium therapy.
Miljković BR; Pokrajac M; Timotijević I; Varagić V
Int Clin Psychopharmacol; 1997 Jul; 12(4):207-12. PubMed ID: 9347381
[TBL] [Abstract][Full Text] [Related]
5. Nonlinear pharmacokinetics of fluvoxamine and gender differences.
Härtter S; Wetzel H; Hammes E; Torkzadeh M; Hiemke C
Ther Drug Monit; 1998 Aug; 20(4):446-9. PubMed ID: 9712472
[TBL] [Abstract][Full Text] [Related]
6. Duloxetine serum concentrations and clinical effects. Data from a therapeutic drug monitoring (TDM) survey.
Waldschmitt C; Vogel F; Pfuhlmann B; Hiemke C
Pharmacopsychiatry; 2009 Sep; 42(5):189-93. PubMed ID: 19724981
[TBL] [Abstract][Full Text] [Related]
7. An open-label pilot study of fluvoxamine for mixed anxiety-depression.
Houck C
Psychopharmacol Bull; 1998; 34(2):225-7. PubMed ID: 9641005
[TBL] [Abstract][Full Text] [Related]
8. Low-dose risperidone augmentation of fluvoxamine treatment in obsessive-compulsive disorder: a double-blind, placebo-controlled study.
Erzegovesi S; Guglielmo E; Siliprandi F; Bellodi L
Eur Neuropsychopharmacol; 2005 Jan; 15(1):69-74. PubMed ID: 15572275
[TBL] [Abstract][Full Text] [Related]
9. [Maprotiline versus fluvoxamine: comparison of their effects on the hypothalamo-hypophyseal-thyroid axis].
De Mendonça Lima CA; Vandel S; Bonin B; Bechtel P; Carron R
Encephale; 1997; 23(1):48-55. PubMed ID: 9172968
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic drug monitoring of plasma fluvoxamine levels for treating bulimia nervosa.
Ikenouchi-Sugita A; Yoshimura R; Hori H; Ueda N; Nakamura J
Psychiatry Clin Neurosci; 2007 Aug; 61(4):452. PubMed ID: 17610677
[No Abstract] [Full Text] [Related]
11. A comparative study of the efficacy and safety profiles between fluvoxamine and nortriptyline in Japanese patients with major depression.
Otsubo T; Akimoto Y; Yamada H; Koda R; Aoyama H; Tanaka K; Mimura M; Nakagome K; Kamijima K
Pharmacopsychiatry; 2005 Jan; 38(1):30-5. PubMed ID: 15706464
[TBL] [Abstract][Full Text] [Related]
12. Predictors of antidepressant response to fluvoxamine obtained using the three-factor structures of the Montgomery and Asberg Depression Rating Scale for major depressive disorders in Japanese patients.
Higuchi H; Sato K; Yoshida K; Takahashi H; Kamata M; Otani K; Yamaguchi N
Psychiatry Clin Neurosci; 2008 Jun; 62(3):301-6. PubMed ID: 18588590
[TBL] [Abstract][Full Text] [Related]
13. [The status of fluvoxamine among the antidepressive agents].
Svestka J; Cesková E; Rysánek R; Obrovská V; Kamenická V
Cesk Psychiatr; 1992 Sep; 88(5):209-19. PubMed ID: 1451197
[TBL] [Abstract][Full Text] [Related]
14. Effects of imipramine, fluvoxamine and depressive mood on autonomic cardiac functioning in major depressive disorder.
Volkers AC; Tulen JH; van den Broek WW; Bruyn JA; Passchier J; Pepplinkhuizen L
Pharmacopsychiatry; 2004 Jan; 37(1):18-25. PubMed ID: 14750044
[TBL] [Abstract][Full Text] [Related]
15. Lithium addition in antidepressant-resistant depression: effects on platelet 5-HT, plasma 5-HT and plasma 5-HIAA concentration.
Birkenhäger TK; van den Broek WW; Fekkes D; Mulder PG; Moleman P; Bruijn JA
Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jun; 31(5):1084-8. PubMed ID: 17467132
[TBL] [Abstract][Full Text] [Related]
16. Fluvoxamine for premenstrual dysphoric disorder: a pilot study.
Freeman EW; Rickels K; Sondheimer SJ
J Clin Psychiatry; 1996; 57 Suppl 8():56-9; discussion 60. PubMed ID: 8698682
[TBL] [Abstract][Full Text] [Related]
17. Notes on the use of fluvoxamine as treatment of depression in HIV-1-infected subjects.
Grassi B; Gambini O; Scarone S
Pharmacopsychiatry; 1995 May; 28(3):93-4. PubMed ID: 7568371
[TBL] [Abstract][Full Text] [Related]
18. Gender differences in the clinical effects of fluvoxamine and milnacipran in Japanese major depressive patients.
Naito S; Sato K; Yoshida K; Higuchi H; Takahashi H; Kamata M; Ito K; Ohkubo T; Shimizu T
Psychiatry Clin Neurosci; 2007 Aug; 61(4):421-7. PubMed ID: 17610668
[TBL] [Abstract][Full Text] [Related]
19. [Comparison of the effectiveness of two treatment strategies in inpatients with a depressive disorder. A double-blind study of imipramine followed by lithium addition versus fluvoxamine followed by lithium addition].
Birkenhäger TK; van den Broek WW; Mulder PG; Bruijn JA; Moleman P
Tijdschr Psychiatr; 2006; 48(4):271-81. PubMed ID: 16955991
[TBL] [Abstract][Full Text] [Related]
20. Comparison of response to fluvoxamine in nondemented elderly compared to younger patients affected by major depression.
Zanardi R; Cusin C; Rossini D; De Ronchi D; Serretti A
J Clin Psychopharmacol; 2003 Dec; 23(6):535-9. PubMed ID: 14624182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
